Abstract
BACKGROUND: We hypothesized that tumor- and hospital-level factors, compared with surgeon characteristics, are associated with the majority of variation in the 12 or more lymph nodes (LNs) examined quality standard for resected colon cancer. STUDY DESIGN: A dataset containing an anonymized surgeon identifier was obtained from the National Cancer Database for stage I to III colon cancers from 2010 to 2017. Multilevel logistic regression models were built to assign a proportion of variance in achievement of the 12 LNs standard among the following: (1) tumor factors (demographic and pathologic characteristics), (2) surgeon factors (volume, approach, and margin status), and (3) facility factors (volume and facility type). RESULTS: There were 283,192 unique patient records with 15,358 unique surgeons across 1,258 facilities in our cohort. Achievement of the 12 LNs standard was high (90.3%). Achievement of the 12 LNs standard by surgeon volume was 88.1% and 90.7% in the lowest and highest quartiles, and 86.8% and 91.6% at the facility level for high and low annual volume quartiles, respectively. In multivariate analysis, the following tumor factors were associated with meeting the 12 LNs standard: age, sex, primary tumor site, tumor grade, T stage, and comorbidities (all p < 0.001). Tumor factors were responsible for 71% of the variation in 12 LNs yield, whereas surgeon and facility characteristics contributed 17% and 12%, respectively. CONCLUSIONS: Twenty-nine percent of the variation in the 12 LNs standard is linked to modifiable factors. The majority of variation in this quality metric is associated with non-modifiable tumor-level factors.
| Original language | English |
|---|---|
| Pages (from-to) | 520-528 |
| Number of pages | 9 |
| Journal | Journal of the American College of Surgeons |
| Volume | 238 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1 2024 |
Bibliographical note
Publisher Copyright:© 2024 by the American College of Surgeons.
Funding
Dr Egger's institute receives research funding from SkylineDX and Dr Egger is a paid consultant to Iovance Biotherapeutics. Dr McMasters is the Editor-in-Chief of Annals of Surgical Oncology. Other authors have nothing to disclose. Support: Dr Feygin is supported by Robert Wood Johnson (grant no. 77407) and Environmental influences on Child Health Outcomes Opportunities and Infrastructure Fund (grant no. EC0560a_OIF). Support: Dr Feygin is supported by Robert Wood Johnson (grant no. 77407) and Environmental influences on Child Health Outcomes Opportunities and Infrastructure Fund (grant no. EC0560a_OIF).
| Funders | Funder number |
|---|---|
| Editor-in-Chief of Annals of Surgical Oncology | |
| Robert Wood Johnson Foundation | 77407, EC0560a_OIF |
ASJC Scopus subject areas
- General Medicine